Needham & Company LLC Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its price target lifted by equities research analysts at Needham & Company LLC from $52.00 to $54.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 56.43% from the company’s previous close.

A number of other research analysts have also recently commented on the company. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. HC Wainwright upped their price objective on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Jefferies Financial Group boosted their target price on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Finally, Wall Street Zen downgraded shares of Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.56.

Liquidia Stock Up 0.4%

Shares of LQDA opened at $34.52 on Thursday. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. Liquidia has a 12 month low of $11.26 and a 12 month high of $46.67. The firm’s 50 day moving average is $37.07 and its 200-day moving average is $30.84. The stock has a market capitalization of $3.00 billion, a PE ratio of -23.97, a P/E/G ratio of 0.60 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company had revenue of $92.02 million during the quarter. Liquidia’s revenue was up 3072.4% compared to the same quarter last year. Equities research analysts forecast that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling

In related news, insider Jason Adair sold 688 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $28,655.20. Following the completion of the transaction, the insider owned 211,169 shares of the company’s stock, valued at $8,795,188.85. This represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev Saggar sold 21,142 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $791,345.06. Following the sale, the insider directly owned 176,883 shares in the company, valued at approximately $6,620,730.69. The trade was a 10.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 212,534 shares of company stock worth $7,964,719 in the last quarter. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently modified their holdings of LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter worth $25,000. Covestor Ltd raised its position in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia during the third quarter valued at about $30,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia during the third quarter worth about $34,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter valued at approximately $25,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non?GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).